close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Gilead Sciences, Inc.

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Gilead Prices $3 Billion of Senior Unsecured Notes
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Sciences Announces First Quarter Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir for HIV Prevention to Further Expand Access
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Extends Tender Offer to Acquire Arcellx
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
FDA Approves Label Update for Kite’s Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Sciences to Present at Upcoming Investor Conference
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
From Gilead Sciences, Inc.
Via Business Wire
Tickers ASMB GILD
News headline image
Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today